Literature DB >> 11399114

Suppression of immune surveillance in melanoma.

M W Biggs1, J E Eiselein.   

Abstract

Numerous reports of IL-10 cytokine secretion by tumor infiltrating cells indicate there is suppression of immune surveillance within the milieu of many melanomas. In this paper we have outlined the suppressor system that best fits the published data. The regulatory system is composed of CD4+ T-lymphocytes which have been activated and programmed to secrete Th2 cytokines. Initially these cells do not secrete cytokines, but subsequently they enter an IL-10 secretory phase as a result of T-T cell interaction. After activation, Th1 programmed T-cells express MHC class II molecules and B7 second signals. When these Th1 T-cells express MHC II molecules containing 'self' polypeptides coupled with faulty B7-H1 second signals they are subject to inactivation by Th2 T-cells. If this system can be inactivated, immunotherapy of melanoma will be more successful. If an antigen can be discovered that stimulates sensitized Th2 T-cells without stimulating Th1 T-cells, this antigen, followed with cyclophosphamide, can be used to destroy the Th2 T-cells in the course of both active and passive immunotherapy. Solubilized MHC II molecules with appropriate 'self' polypeptides should qualify as such an antigen. We postulate such an antigen can be prepared using poliovirus 1 (Sabin) to lyse melanoma tissue cultures. Copyright 2001 Harcourt Publishers Ltd.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11399114     DOI: 10.1054/mehy.2000.1211

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  6 in total

Review 1.  Gentian violet: a 19th century drug re-emerges in the 21st century.

Authors:  Alexander M Maley; Jack L Arbiser
Journal:  Exp Dermatol       Date:  2013-12       Impact factor: 3.960

2.  Modulation of bone morphogenic protein signaling in T-cells for cancer immunotherapy.

Authors:  Michal Kuczma; Agnieszka Kurczewska; Piotr Kraj
Journal:  J Immunotoxicol       Date:  2013-12-19       Impact factor: 3.000

3.  Pivotal molecules of MHC I pathway in human primary hepatocellular carcinoma.

Authors:  Wei Chen; Mei-Ying Cai; Da-Peng Wei; Xia Wang
Journal:  World J Gastroenterol       Date:  2005-06-07       Impact factor: 5.742

4.  Effects of cryopreservation and phenylacetate on biological characters of adherent LAK cells from patients with hepatocellular carcinoma.

Authors:  Ning Zheng; Sheng-Long Ye; Rui-Xia Sun; Yan Zhao; Zhao-You Tang
Journal:  World J Gastroenterol       Date:  2002-04       Impact factor: 5.742

5.  Anti-IL-10-mediated Enhancement of Antitumor Efficacy of a Dendritic Cell-targeting MIP3α-gp100 Vaccine in the B16F10 Mouse Melanoma Model Is Dependent on Type I Interferons.

Authors:  James T Gordy; Kun Luo; Brian Francica; Charles Drake; Richard B Markham
Journal:  J Immunother       Date:  2018-05       Impact factor: 4.456

6.  IL-10 expression by primary tumor cells correlates with melanoma progression from radial to vertical growth phase and development of metastatic competence.

Authors:  Eijun Itakura; Rong-Rong Huang; Duan-Ren Wen; Eberhard Paul; Peter H Wünsch; Alistair J Cochran
Journal:  Mod Pathol       Date:  2011-02-11       Impact factor: 7.842

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.